– November 1, 2006
November 1, 2006
View Issues
-
Rituximab-Fludarabine Combinations and the Risk of Non-Neutropenic Infection
Rituximab has proven an effective adjunct to various chemotherapy regimens in the treatment of lymphoma. When used alone or with combinations such as CHOP, hypogammaglobulinemia occurs relatively infrequently and no increased risk of infection has been reported. -
Prolonged Hormone Replacement Therapy Linked to Increased Ovarian Cancer Risk
There have been conflicting reports on the risks of ovarian cancer in users of hormone replacement therapy. In the NIH-AARP Diet and Health Study Cohort, analysis of various aspects of HRT and the development of ovarian cancer in approximately 100,000 women aged 50-71 years was undertaken. -
Initial Experiences with Bevacizumab in Recurrent Ovarian Cancer: Ouch!
Combination bevacizumab therapy demonstrated activity in heavily pretreated women with ovarian cancer. Gastrointestinal perforations were identified in 9%. -
No Benefit to Upfront Autologous Transplant for Follicular Lymphoma
The role of autologous stem cell transplant (ASCT) in newly diagnosed follicular lymphoma (FL) patients is controversial. -
Node-Negative Breast Cancer in Very Young Women Requires Tailored Adjuvant Therapy
Breast cancer in women younger than age 35 is uncommon, but is known to be associated with more negative clinical outcomes. -
Pharmacology Watch
Wait and see prescriptions (WASP) is a new concept for the treatment of otitis media in children. -
Clinical Briefs in Primary Care Supplement